Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

B. Watts, Nelson; P. Bilezikian, John; Usiskin, Keith; Edwards, Robert; Desai, Mehul; Law, Gordon; Meininger, Gary

doi:10.1210/jc.2015-3167

Public

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

Published in The Journal of Clinical Endocrinology & Metabolism • Nov 18, 2015

Authors:

Nelson B. Watts

John P. Bilezikian

Keith Usiskin

Abstract

CONTEXT: Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM). OBJECTIVE: The purpose of this study was to describe the effects of canagliflozin on bone fracture risk. DESIGN AND SETTING: This was a randomized phase 3 study in patients with T...

Subject

Canagliflozin

Medicine

Type 2 Diabetes Mellitus

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!